- Home
- CABA vs BTMD Comparison
CABA vs BTMD Comparison
Compare CABA & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- BTMD
- Stock Information
- Founded
- CABA 2017
- BTMD 2012
- Country
- CABA United States
- BTMD United States
- Employees
- CABA N/A
- BTMD N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- BTMD Medicinal Chemicals and Botanical Products
- Sector
- CABA Health Care
- BTMD Health Care
- Exchange
- CABA Nasdaq
- BTMD Nasdaq
- Market Cap
- CABA 149.3M
- BTMD 127.8M
- IPO Year
- CABA 2019
- BTMD N/A
- Fundamental
- Price
- CABA $1.71
- BTMD $3.13
- Analyst Decision
- CABA Strong Buy
- BTMD Buy
- Analyst Count
- CABA 7
- BTMD 2
- Target Price
- CABA $14.29
- BTMD $6.00
- AVG Volume (30 Days)
- CABA 1.3M
- BTMD 178.8K
- Earning Date
- CABA 08-07-2025
- BTMD 08-06-2025
- Dividend Yield
- CABA N/A
- BTMD N/A
- EPS Growth
- CABA N/A
- BTMD 642.53
- EPS
- CABA N/A
- BTMD 0.88
- Revenue
- CABA N/A
- BTMD $199,073,000.00
- Revenue This Year
- CABA N/A
- BTMD $5.87
- Revenue Next Year
- CABA N/A
- BTMD $8.59
- P/E Ratio
- CABA N/A
- BTMD $3.51
- Revenue Growth
- CABA N/A
- BTMD 6.32
- 52 Week Low
- CABA $0.99
- BTMD $2.76
- 52 Week High
- CABA $6.26
- BTMD $6.98
- Technical
- Relative Strength Index (RSI)
- CABA 57.70
- BTMD 32.15
- Support Level
- CABA $1.26
- BTMD $2.76
- Resistance Level
- CABA $1.56
- BTMD $3.01
- Average True Range (ATR)
- CABA 0.12
- BTMD 0.24
- MACD
- CABA 0.00
- BTMD -0.15
- Stochastic Oscillator
- CABA 92.78
- BTMD 10.38
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.